Pharsight

Drugs that contain Methylnaltrexone Bromide

1. Relistor patents expiration

RELISTOR's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8552025 SALIX PHARMS Stable methylnaltrexone preparation
Apr, 2024

(a month from now)

US10376584 SALIX PHARMS Stable pharmaceutical formulations of methylnaltrexone
Apr, 2024

(a month from now)

US9669096 SALIX PHARMS Stable pharmaceutical formulations of methylnaltrexone
Apr, 2024

(a month from now)

US8420663 SALIX PHARMS Peripheral opioid receptor antagonists and uses thereof
Sep, 2029

(5 years from now)

US9492445 SALIX PHARMS Peripheral opioid receptor antagonists and uses thereof
Sep, 2029

(5 years from now)

US8822490 SALIX PHARMS Peripheral opioid receptor antagonists and uses thereof
Sep, 2029

(5 years from now)

US9180125 SALIX PHARMS Peripheral opioid receptor antagonists and uses thereof
Sep, 2029

(5 years from now)

US8247425 SALIX PHARMS Peripheral opioid receptor antagonists and uses thereof
Dec, 2030

(6 years from now)

Market Authorisation Date: 24 April, 2008

Treatment: Treatment of opioid-induced constipation

Dosage: SOLUTION;SUBCUTANEOUS

How can I launch a generic of RELISTOR before it's drug patent expiration?
More Information on Dosage

RELISTOR family patents

Family Patents

2. Relistor patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9492445 SALIX Peripheral opioid receptor antagonists and uses thereof
Sep, 2029

(5 years from now)

US8420663 SALIX Peripheral opioid receptor antagonists and uses thereof
Sep, 2029

(5 years from now)

US9724343 SALIX Peripheral opioid receptor antagonists and uses thereof
Sep, 2029

(5 years from now)

US9180125 SALIX Peripheral opioid receptor antagonists and uses thereof
Sep, 2029

(5 years from now)

US8956651 SALIX Oral formulations and lipophilic salts of methylnal trexone
Mar, 2031

(7 years from now)

US10376505 SALIX Oral formulations and lipophilic salts of methylnaltrexone
Mar, 2031

(7 years from now)

US9314461 SALIX Oral formulations and lipophilic salts of methylnaltrexone
Mar, 2031

(7 years from now)

US10307417 SALIX Oral formulations and lipophilic salts of methylnaltrexone
Mar, 2031

(7 years from now)

US8524276 SALIX Oral formulations and lipophilic salts of methylnaltrexone
Mar, 2031

(7 years from now)

Market Authorisation Date: 19 July, 2016

Treatment: Treatment of opioid-induced constipation

Dosage: TABLET;ORAL

How can I launch a generic of RELISTOR before it's drug patent expiration?
More Information on Dosage

RELISTOR family patents

Family Patents